Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)
about
Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)
description
scientific article published on 28 January 2019
@en
name
Randomized phase II study eval ...... t cancer (NorBreast-231 trial)
@en
type
label
Randomized phase II study eval ...... t cancer (NorBreast-231 trial)
@en
prefLabel
Randomized phase II study eval ...... t cancer (NorBreast-231 trial)
@en
P2093
P1433
P1476
Randomized phase II study eval ...... t cancer (NorBreast-231 trial)
@en
P2093
Bozena Kukielka-Budny
Ewa Szombara
Giuliano Santos Borges
Gustavo Villanova
Helene Hervieu
Laura Garcia-Estevez
Manuel Ruiz-Borrego
Matti Aapro
Mélanie Groc
Roberto Hegg
P356
10.1016/J.BREAST.2019.01.009
P577
2019-01-28T00:00:00Z